Frank Pasqualone - 19 Nov 2021 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Reporting relationship: SVP, CHIEF BUSINESS OFFICER
Issuer ticker: TBPH
Reported as of: 19 Nov 2021
Net transaction value: -$31,592
SEC form: 4
Accepted by SEC: 23 Nov 2021, 19:25:39 UTC
Prior SEC filing: 24 Aug 2021
Next SEC filing: 22 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Brett A. Grimaud, Attorney-in-Fact

Key filing fact

Frank Pasqualone filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 23 Nov 2021.

Key facts

This page summarizes Frank Pasqualone's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Nov 2021, 19:25.

Change

Previous filing in this sequence was filed on 24 Aug 2021.
Current net transaction value: -$31,592.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TBPH transaction

Ordinary Shares

Tax liability

Transaction value: $31,592
Shares: -3,779
Change %: -0.87%
Price: $8.36
Shares after: 429,783
Date: 19 Nov 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.